Search Share Prices

ClearStar integrates mobile drug testing solution with Abbott Laboratories

Background check technology and service provider ClearStar announced on Wednesday that its ClearMD mobile drug testing solution was now integrated with Abbott Laboratories.
The AIM-traded firm said the deal would "significantly expand" the number of test collection sites where ClearStar's mobile solution for medical test ordering could be used.

In addition to its existing integrations with LabCorp and Quest Diagnostics, ClearStar said it was now the only provider offering paperless medical screening with a fully-customisable user platform across all three of the major laboratories in the US.

By broadening the number of test collection sites, ClearStar said it was not only expanding the services it offered, but also enhancing the convenience for employees by offering a greater choice of location, which also assisted employers by increasing the speed of the process.

In addition, ClearStar said it expected to benefit from the economies of scale associated with engaging multiple large suppliers.

"We are very proud to have achieved this integration with Abbott Laboratories, which makes ClearStar the only provider of paperless medical testing with a fully customisable user platform that is integrated with all three major US labs," said ClearStar CEO Robert Vale.

"By increasing the number of medical test sites available through our smartphone-enabled ClearMD, we can provide a better experience for the employee or candidate by offering more choice and less hassle as well as benefit the employer by getting their employee to work quicker."

Vale said the integration, which was the result of substantial efforts by, and the expertise of, the firm's IT engineers, further enhanced its competitive position in the market.

"We hope to leverage this as we continue to receive increasing demand driven by the strength of our differentiated offer in an ever-more mobile society along with changes such as the deregulation of recreational drug use.

"As a result, we look forward to delivering even greater growth in our medical information services."

Related Share Prices